logo

SOPH

Sophia Genetics·NASDAQ
--
--(--)
--
--(--)
9.85 / 10
Outperform

The firm exhibits exceptional fundamental strength scoring 9.8/10. Supportive aspects include high net profit attributable to shareholders ratio and strong year-over-year revenue growth, while limitations involve negative profit margins and cash flow inefficiencies. Overall verdict: very promising.

Fundamental(9.85)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-1.00
Score2/3
Weight214.19%
1M Return3.00%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-97.93%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value17.12
Score2/3
Weight-9.62%
1M Return-0.16%
Net cash flow from operating activities / Operating revenue (%)
Value-49.95
Score1/3
Weight-106.74%
1M Return-2.03%
Net income-Revenue
Value-0.17
Score1/3
Weight-43.71%
1M Return-0.69%
Net profit margin (%)
Value-107.66
Score1/3
Weight-85.19%
1M Return-1.60%
Current assets turnover ratio
Value0.55
Score2/3
Weight17.23%
1M Return0.26%
EBIT / Total operating revenue (%)
Value-101.73
Score1/3
Weight-122.97%
1M Return-2.44%
Asset-MV
Value-0.50
Score3/3
Weight434.79%
1M Return5.62%
Net profit / Total operating revenue (%)
Value-107.66
Score1/3
Weight-100.05%
1M Return-1.90%
Is SOPH undervalued or overvalued?
  • SOPH scores 9.85/10 on fundamentals and holds a Discounted valuation at present. Backed by its -76.12% ROE, -102.29% net margin, -4.42 P/E ratio, 5.35 P/B ratio, and -2.75% earnings growth, these metrics solidify its Outperform investment rating.